Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783919 | 1.00 | IDO1 (0.39) | IDO1FFAR1ALDH1A1MEN1MAPT | |
| SCHEMBL21783901 | 0.92 | ALDH1A1 (0.35) | IDO1FFAR1ALDH1A1PTGS2SMN1; SMN2 | |
| SCHEMBL21783850 | 0.92 | ALDH1A1 (0.35) | IDO1FFAR1ALDH1A1PTGS2SMN1; SMN2 | |
| SCHEMBL21773813 | 0.87 | IDO1 (0.35) | IDO1FFAR1ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL21773747 | 0.87 | IDO1 (0.35) | IDO1FFAR1ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL21773901 | 0.87 | IDO1 (0.35) | IDO1FFAR1ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL21773745 | 0.87 | IDO1 (0.35) | IDO1FFAR1ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL21773815 | 0.87 | IDO1 (0.35) | IDO1FFAR1ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL21773749 | 0.87 | IDO1 (0.35) | IDO1FFAR1ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL21773948 | 0.87 | IDO1 (0.35) | IDO1FFAR1ALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253525-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200069695-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253525-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | IDO1 1/4885FFAR1 3772/4885ALDH1A1 952/4885 |
| US-20200069695-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | IDO1 1/4885FFAR1 3772/4885ALDH1A1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.